Dr. Quin Xie is a Postdoctoral Fellow in the Department of Genetics and Genome Biology at The Hospital for Sick Children. Her PhD research investigates how environmental and microbial exposures shape immune development and metabolic health trajectories in children, with a focus on understanding the role of gut microbiota in the risk of type 1 and type 2 diabetes. Her doctoral work examined the interplay between gut microbiota, immune responses, and therapeutic outcomes in youth-onset diabetes. She developed innovative approaches to identify immune–microbe interactions that predict response to teplizumab, the first FDA-approved immunotherapy for type 1 diabetes prevention. In addition, her studies in adolescent obesity identified altered gut microbial biomass and systemic inflammation are linked to early metabolic dysfunction.
Currently, Quin leads a longitudinal study following mothers with and without type 1 diabetes and their children to investigate how maternal microbiota, dietary, and immune factors influence offspring autoimmune risk. Her research contributes to the Collaborative Centre’s mission by illuminating how ecological and environmental determinants influence immune health across generations. By integrating microbiology, immunology, and statistical analysis, her work advances sustainable and preventive care strategies that address both chronic disease risk and environmental health equity.
Beyond research, Quin is actively engaged in mentorship, equity and inclusion initiatives, and interdisciplinary teaching. She has served on graduate student committees, organized scientific workshops, and led data-driven projects to improve academic policy and student well-being. Through membership in the Collaborative Centre, she aims to connect with researchers and practitioners working at the interface of climate, health, and sustainable care to foster collaborative, evidence-based solutions.